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Objectives: To date, no mucopolysaccharidosis type II (MPS II) measure capturing 
disease severity exists other than classifying patients with and without cognitive 
impairment. This study aimed to develop a clinician-reported outcome (ClinRO) 
to assess somatic and central nervous system (CNS) severity in patients with MPS 
II. MethOds: Following a literature review to identify key indicators of MPS II sever-
ity and interviews with pediatric specialists, two interactive video conferences with 
clinicians from the Hunter Outcome Survey (HOS) working groups were conducted 
to review the draft instrument and discuss definitions and descriptions of observ-
able signs and symptoms and objective clinical parameters. Patient vignettes based 
on hypothetical cases with different ranges of severity were developed to evalu-
ate inter-and intra-rater reliability. Further refinement of items and descriptions 
were discussed in additional expert panels to obtain consensus on content validity, 
including wording and importance of individual items. Results: The current ver-
sion of the Disease Severity Score (DSS) comprises two components, somatic and 
CNS, with 17 items covering 11 domains altogether. The somatic component (11 
items) includes respiratory, hearing, cardiac, neurology, and orthopaedic domains. 
The CNS component (6 items) covers cognition, language & communication, activity 
level & focus, toileting, sleeping disorder, and seizures. Most items used a severity 
rating (normal, mild, moderate, and severe) accompanied by a clinical description; 
some items in the Somatic component also contain objective clinical parameters. 
Intra-rater reliability was demonstrated for all items (κ appa> 0.80). cOnclusiOns: 
A novel and innovative approach was used in the development of this ClinRO with 
the consensus of experts in MPS II. The DSS is intended to assess disease severity 
using observable signs and symptoms, track somatic and CNS disease severity and 
progression over time and to compare severity of MPS II across centers interna-
tionally. A scoring algorithm and assessments of validity and responsiveness are 
currently being developed.
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Objectives: To analyze the cost variation of oral anti-diabetics of different generic 
drugs sold at Jan Avushadhi and jeevanadhara and Retail pharmacy available brand 
names of single compound and combination compounds to evaluate the differ-
ence in cost , percentage variation of cost. MethOds: Cost of single and combina-
tion compound drugs manufactured by different companies, in the same strength, 
number and dosage form was obtained from Current Index of Medical Specialties” 
July-October 2014 and jan avushdhi,jeevandharaa drugs were compared upto 
February -2015. Results: In Single compound drug usage, among sulfonylurea 
group of drugs, Glibenclamide (2 mg) shows maximum price variation of 1980%, 
while Glipizide (10mg) shows variation of 55.61%. In Biguanides & Thizolidinediones 
groups Of drugs Metformin (1000 mg) show Maximum price variation is 125.37%, 
Metformin (500 mg) leat variation is 30 % and Piglitazone (30mg) show Maxmum 
variation 3060.97% and least variation Pioglitazoe (15 mg) is 3275 respectively. . 
In α -glucosidases inhibitor group of drugs,Miglitol shows maximum price varia-
tion of 135.50 % and Minimum variation is 41.93 %. Meglitinides group of drugs. 
In this group, Rapaglinide (0.5 mg) shows Maximum price variation of 79.25 % and 
Minimum variation is 60 % respectively. Dipeptidyl peptidase IV inhibitors (e.g., 
Sitagliptin), group Sitagliptin (100 mg) shows Maximum price variation of 902.3 %. 
In combination therapiesGlibenclamide + Metformin (5 mg+ 500 mg) combination 
shows the maximum variation up to 2400 % and Glipizide + Metformin (2.5mg + 
250mg) showed minimum price variation of 28.60% respectively. cOnclusiOns: 
Study has concluded that the cost variation increases when competition between 
the manufacturing companies and generic companies. cost which company provid-
ing less cost and whether these drugs are available janavushadhi or jeevandhara or 
generic pharmacy shops. So that we can minimize the cost burden on consumers.
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Objectives: The purpose of this study is to examine the measurement invari-
ance of the WHOQOL-OLD Module across different demographic groups in Taiwan’s 
elderly people. By testing the differential item functioning (DIF), the presence of DIF 
indicates measurement variance. In other words, item score of measurement scale 
is dependent on some irrelevant characteristics. If this condition is observed the 
interpretation of items would be confounded. MethOds: A total sample 524 par-
ticipants involved in this study, but only 503 participants (96%) completed the whole 
questionnaire. The questionnaire included the WHOQOL-OLD and the demographic 
characteristics (age, gender, and education). Multiple-indicator multiple-cause 
latent variable (MIMIC) model was used to explore the relationship between the 
latent factors and demographic variables. Data was analyzed by using the Mplus7.0 
and SAS9.4 software. Results: Multiple-indicator multiple-cause latent variable 
model showed significant differences were observed on sensory abilities, death and 
dying for different age and education and on social participation only for different 
education. However, the significant differences can be eliminated when adjusting 
for DIF on item1 and item18, respectively, on sensory abilities and social participa-
tion. cOnclusiOns: The result implies that age and education should be controlled 
when comparing sensory abilities, death and dying and social participation facets. 
Objectives: To define the term ‘usually’ in order to ascertain potential pitfalls in 
its translation in any future target language. MethOds: This posed a particular 
issue in translation of the ADSC (Activities of Daily Living Inventory) in which the 
term appears 28 times in the form of either ‘usual’ or ‘usually’. Discussion with 
the client confirmed the desired and contextual meaning of the term for this 
instrument, with additional guidance from clinicians, and the issue was discussed 
extensively with linguists for all 31 languages in this particular study. Results: 
After in-depth discussion between ICON Language Services and the client, it was 
agreed that a more specific definition of ‘usually’ should be checked and applied 
to the translations so as to avoid risk in incorrect data collection and poten-
tially causing offence to the target population. Concern was raised that the term 
could be mistaken for ‘normally’, which could lead to specifying what is ‘normal’ 
vs ‘abnormal’, i.e. making a judgement about the behaviour of the subject. We 
ensured that the term ‘usually’ was not translated as ‘normally’, did not imply 
‘normal’ vs ‘abnormal’ behaviour and rendered the concept of frequency present 
in the source term ‘usual’. cOnclusiOns: In this project, it was vital that the term 
‘usually’ should carry a wholly descriptive value, meaning that the phenomenon 
in question occurs with high frequency or by habit/custom. This should not be 
confused with the concept ‘normally’, which can carry a prescriptive connotation 
implying an underlying rule/order. To avoid any ambiguous or incorrect transla-
tion of the word ‘usually’, it is strongly advised that this be clearly defined from 
the start and checked throughout the linguistic validation process. Discussion 
between the client and linguistic staff reveals the importance of close collabora-
tion in resolving terminology issues and improving data integrity through the 
conceptual equivalence of translations.
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Objectives: The FSIQ-RMS™ is the first patient-reported outcome (PRO) measure 
of fatigue in RMS developed according to the 2009 FDA PRO guidance.1 A qualita-
tive study was conducted to provide evidence of adequacy after adapting the FSIQ-
RMS™ from paper to an electronic handheld device (eDiary). MethOds: Migration 
of the FSIQ-RMS™ to a BLU Life Play® Android™ smartphone involved modifying the 
instructions and landscape formatting with one item per screen. The FSIQ-RMS™ 
was administered to adult RMS patients at 2 US sites in a cross-sectional study. After 
training on the eDiary, each participant completed paper and electronic versions of 
the FSIQ-RMS™ in randomized order, then a device-usability questionnaire followed 
by one-on-one semi-structured cognitive interviews to assess comprehension of the 
FSIQ-RMS™, comparison between paper and electronic platforms, and usability of 
the eDiary. Results: The migration study included 10 RMS patients (mean age 42 
[range 27–54] years; 70% female), 8 with relapsing-remitting MS and 2 with relapsing 
secondary-progressive MS; mean±SD Expanded Disability Status Scale score 3.2±1.9. 
All participants understood and were able to view the FSIQ-RMS™ instructions, ques-
tions and response options, were able to answer the questions, and reported that the 
eDiary was easy to use. Based on participant comments, examples were added to one 
item to clarify the intended meaning. Discrepancies in response between formats 
were found, but most were not attributed to the device. Many participants (7/10, 70%) 
spontaneously reported preferring the eDiary to the paper format. Three participants 
suggested increasing the touch-sensitivity of the “Next” button; 5 suggested that they 
would have preferred a larger device (n= 3) and/or font size (n= 4). cOnclusiOns: 
Results confirmed the conceptual equivalence of the FSIQ-RMS™ eDiary to the paper 
version and its appropriateness for use with RMS patients. Further validation of the 
FSIQ-RMS™ will be conducted in a Phase III RMS trial. 1Value Health 2015;18(3):A26.
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Objectives: This study sought to determine the benefits to sponsor, developer, 
and translation provider of monitored cognitive debriefing interviews with patient 
questionnaires. Monitored cognitive debriefing (CD) was theorized to be particularly 
suitable for newly-developed questionnaires with minimal or no previous linguistic 
validation (LV), and for adapted questionnaires (i.e., a disease-specific instrument 
adapted to a new disease). MethOds: Thirty (30) CD interviews were carried out on 
a newly-developed patient instrument in six languages. Of those, sixteen (16) inter-
views were monitored by the sponsor. All languages were selected by the sponsor and 
a percentage of those interviews were monitored, the first languages to undergo LV. 
The translation provider recruited patients, provided interpreters, secured facilities 
with two-way mirrors and audio-visual recording capabilities, and performed the 
interviews. The monitor noted any sub-threshold issues that were outside of typical 
LV data capture rubric. Upon noting such issues in more than one country, the test 
authors would convene a meeting to consider if the PRO linguistic validation protocol 
or PRO source instrument required revision. Results: The monitor suggested follow-
up questions as needed during the CD interviews, tailoring the process to target spe-
cific dimensions of the PRO. Issues were tracked across languages by the monitor, and 
the interviewer asked subjects for their preference for alternative translations, when 
suggested by the monitor. Compared to those interviews which were unmonitored, 
on average, subjects made more comments overall, and more comments leading to a 
translation revision. cOnclusiOns: Monitored interviews are beneficial for the vali-
dation of newly-developed or adapted instruments. This augmentation to CD provides 
a means of vendor management and early identification of issues during LV that are 
outside of the typical data capture rubric. The process enables the sponsor to suggest 
follow-up questions or modifications on-site, thus correcting issues preemptively that 
may negatively impact understanding and subsequent data pooling.
